medigraphic.com
ISSN 1817-5996 (Electronic)

2015, Number 2

<< Back Next >>

Rev Cub de Reu 2015; 17 (2)

Correlation of C-reactive protein and atherosclerosis in patients with systemic lupus erythematosus

Hernández MY, Guibert TZM, Reyes LGA

Language: Spanish
References: 21
Page: 126-131
PDF size: 416.91 Kb.


ABSTRACT

Method: a descriptive, prospective study of cases and controls with patients with a diagnosis of systemic lupus erythematosus attended in the Center of Rheumatology and CIMEQ, Havana, from July 2010 to July 2012.
Objective: to evaluate the correlation between the values of reactive protein *c and the presence of subclinical atherosclerosis in patients with them.
Results: the study included 62 patients with THEM. The average age in the group of patients with THEM was 40.9 years old, predominating, the rank between 35-44 years old. There was prevalence of the no white ethnic group either in patients or controls: 67.7 %. atheromatose plate was observed in 22 patients (35.5 %), out of which 13,6 % had some coronary event. Positive reactive Protein C was corroborated in 41 patients, out of which 22 presented atheromatose plate.
Conclusion: the concentration of C-reactive protein can be used as a marker of subclinical atherosclerosis, since its concentration correlates with the intimate-average thickness and with calcified deposits in the intimate average complex.


REFERENCES

  1. Battagliotti CA, Kilstein J, Gentiletti AA, Pons Estel B. Lupus Eritematoso Sistémico. Aspectos clínicos y terapéuticos. 2da. Buenos Aire Ed: CB Eitores; 1998. p. 187-94.

  2. Petri M. La cohorte de Lupus de Hopkins. Puesta al día. Clínic Rheumatic Disease of North America (Edición Española). 2000;(2):203-17.

  3. Font J. Khamashta M, Vilardell M. Lupus Eritematoso Sistémico. Segunda parte, Capítulo VI. Barcelona: Ed. MRA, S.L; 1996. p. 73-239.

  4. Hetjmancik MR, Wright IC, Quint R, Jennings, FL The cardiovascular manifestations of systemic lupus erythematosus. Am Heart J. 1964;68:119-30.

  5. Jensen G, Sigurd B. Systemic lupus erythematosus anda cute myocardial infarction. Chest. 1973;64:653-4.

  6. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA., Smythe HA, Ogryzlo MA.. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60:221-5.

  7. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal mortality pattern revisited. QJM. 1985;55:87-98.

  8. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995;22:1259-64.

  9. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurements of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988;31:817-25.

  10. Cisternas M. Ateroesclerosis en Enfermedades Reumatológicas. ¿Mito o Realidad?. Reumatología. 2006;22(1):9-13.

  11. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-4.

  12. Manzi S, Meilahn EN, Rairie JE. Age-specific incidente rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408-15.

  13. Rahman P, Urowitz M, Gladman D, Bruce I, Genest J. Contribution of tradicional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol. 1999;26:2363-8.

  14. Esdaile J, Abrahamowicz M, Grodsicky T, Li Y, Panaritis C, Berger RD. Senécal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;(10):2331-37.

  15. Ross R. Atherosclerosis – An inflammatory disease. N Engl J Med. 1999;340:115-26.

  16. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355-74.

  17. Lahoz C, Mostaza J M. La ateroesclerosis como enfermedad sistémica. Rev. Esp Cardiol. 2007;60(2):184-95.

  18. Petri M, Pérez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513-9.

  19. Toloza SM, Uribe AG, McGwin G Jr, Alarcon GS, Fessler BJ, Bastian HM, et al, for the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004;50:3947-57.

  20. Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events (AVE) in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007;34:70-5.

  21. Urowitz M. B, Gladman D,1 Ibañez D. Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus. Arthritis Care & Research. 2010;62(6):881-7.




2020     |     www.medigraphic.com